Drug-binding energetics of human α-1-acid glycoprotein assessed by isothermal titration calorimetry and molecular docking simulations

Journal of Molecular Recognition

Volumn 25, Issue 12, 2012, Pages 642-656

  Huang, Johnny X ^a   Cooper, Matthew A ^a   Baker, Mark A ^b   Azad, Mohammad A K ^c   Nation, Roger L ^c   Li, Jian ^c   Velkov, Tony ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c MONASH UNIVERSITY   (Australia)

Author keywords

drug binding; human 1 acid glycoprotein; thermodynamics

Indexed keywords

DRUG; LIGAND; OROSOMUCOID;

ARTICLE; BINDING SITE; BIOLOGICAL MODEL; CALORIMETRY; CHEMICAL PHENOMENA; CHEMICAL STRUCTURE; CHEMISTRY; ENERGY METABOLISM; HUMAN; METABOLISM; METHODOLOGY; MOLECULAR DOCKING; PHYSIOLOGY; PROTEIN BINDING; TEMPERATURE; THERMODYNAMICS; TITRIMETRY;

BINDING SITES; CALORIMETRY; ENERGY METABOLISM; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIGANDS; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; OROSOMUCOID; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; TEMPERATURE; THERMODYNAMICS; TITRIMETRY;

EID: 84870508287     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.2221     Document Type: Article

References (73)

1. Aki H, Yamamoto M,. 1989. Thermodynamics of the binding of phenothiazines to human plasma, human serum albumin and alpha 1-acid glycoprotein: a calorimetric study. J. Pharm. Pharmacol. 41: 674-679.
2. Baker BM, Murphy KP,. 1996. Evaluation of linked protonation effects in protein binding reactions using isothermal titration calorimetry. Biophys. J. 71: 2049-2055.
3. Baker BM, Murphy KP,. 1997. Dissecting the energetics of a protein-protein interaction: the binding of ovomucoid third domain to elastase. J. Mol. Biol. 268: 557-569.
4. Broecker J, Vargas C, Keller S,. 2011. Revisiting the optimal c value for isothermal titration calorimetry. Anal. Biochem. 418: 307-309.
5. Chen IJ, Foloppe N,. 2010. Drug-like bioactive structures and conformational coverage with the LigPrep/ConfGen suite: comparison to programs MOE and catalyst. J. Chem. Inf. Model. 50: 822-839.
6. Czodrowski P, Sotriffer CA, Klebe G,. 2007. Protonation changes upon ligand binding to trypsin and thrombin: structural interpretation based on pK(a) calculations and ITC experiments. J. Mol. Biol. 367: 1347-1356.
7. Dente L, Ciliberto G, Cortese R,. 1985. Structure of the human alpha 1-acid glycoprotein gene: sequence homology with other human acute phase protein genes. Nucleic Acids Res. 13: 3941-3952.
8. Dente L, Pizza MG, Metspalu A, Cortese R,. 1987. Structure and expression of the genes coding for human alpha 1-acid glycoprotein. EMBO J. 6: 2289-2296.
9. Dente L, Ruther U, Tripodi M, Wagner EF, Cortese R,. 1988. Expression of human alpha 1-acid glycoprotein genes in cultured cells and in transgenic mice. Genes Dev. 2: 259-266.
10. Dudley MN, Blaser J, Gilbert D, Zinner SH,. 1990. Significance of "extravascular" protein binding for antimicrobial pharmacodynamics in an in vitro capillary model of infection. Antimicrob. Agents Chemother. 34: 98-101.
11. Dullweber F, Stubbs MT, Musil D, Sturzebecher J, Klebe G,. 2001. Factorising ligand affinity: a combined thermodynamic and crystallographic study of trypsin and thrombin inhibition. J. Mol. Biol. 313: 593-614.
12. Eap CB, Baumann P,. 1988. Isoelectric focusing of alpha-1 acid glycoprotein (orosomucoid) in immobilized pH-gradients with 8 M urea: detection of its desialylated variants using an alkaline phosphatase-linked secondary antibody system. Electrophoresis 9: 650-654.
13. Eap CB, Cuendet C, Baumann P,. 1988a. Binding of amitriptyline to alpha 1-acid glycoprotein and its variants. J. Pharm. Pharmacol. 40: 767-770.
14. Eap CB, Cuendet C, Baumann P,. 1988b. Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. Naunyn Schmiedebergs Arch. Pharmacol. 337: 220-224.
15. 1-acid glycoprotein. Clin. Pharmacol. Ther. 47: 338-346.
16. Eap CB, Fischer JF, Baumann P,. 1991. Variations in relative concentrations of variants of human alpha 1-acid glycoprotein after acute-phase conditions. Clin. Chim. Acta 203: 379-385.
17. Flower DR,. 1996. The lipocalin protein family: structure and function. Biochem. J. 318 (Pt 1): 1-14.
18. Flower DR, North AC, Sansom CE,. 2000. The lipocalin protein family: structural and sequence overview. Biochim. Biophys. Acta 1482: 9-24.
19. Fournier T, Medjoubi NN, Porquet D,. 2000. Alpha-1-acid glycoprotein. Biochim. Biophys. Acta 1482: 157-171.
20. Freire E., 2009. A thermodynamic approach to the affinity optimization of drug candidates. Chem. Biol. Drug Des. 74: 468-472.
21. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al,. 2004. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47: 1739-1749.
22. Frisk-Holmberg M, van der Kleijn E,. 1972. The relationship between the lipophilic nature of tricyclic neuroleptics and antidepressants, and histamine release. Eur. J. Pharmacol. 18: 139-147.
23. Goldberg RN, Kishore N, Lennen RM,. 2002. Thermodynamic quantities for the ionization reactions of buffers. J. Phys. Chem. Ref. Data 31: 231-370.
24. Gomez J, Freire E,. 1995. Thermodynamic mapping of the inhibitor site of the aspartic protease endothiapepsin. J. Mol. Biol. 252: 337-350.
25. Greenblatt DJ, Sellers EM, Koch-Weser J,. 1982. Importance of protein binding for the interpretation of serum or plasma drug concentrations. J. Clin. Pharmacol. 22: 259-263.
26. Hervé F., 1993. Fractionation of the genetic variants of human alpha 1-acid glycoprotein in the native form by chromatography on an immobilized copper(II) affinity adsorbent. Heterogeneity of the separate variants by isoelectrofocusing and by concanavalin A affinity chromatography. J. Chromatogr. 615: 47-57.
27. Hervé F, Gomas E, Duché JC, Tillement JP,. 1993a. Fractionation of the genetic variants of human alpha(1)-acid glycoprotein in the native form by chromatography on an immobilized copper(II) affinity adsorbent. heterogeneity of the separate variants by isoelectrofocusing and by concanavalin A affinity chromatography. J. Chromatogr. 615: 47-57.
28. Hervé F, Gomas E, Duché JC, Tillement JP,. 1993b. Evidence for differences in the binding of drugs to the two main genetic variants of human alpha 1-acid glycoprotein. Br. J. Clin. Pharmacol. 36: 241-249.
29. Hervé F, Duché JC, d'Athis P, Marche C, Barre J, Tillement JP,. 1996. Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics 6: 403-415.
30. Hervé F, Caron G, Duché JC, Gaillard P, Abd Rahman N, Tsantili-Kakoulidou A, Carrupt PA, d'Athis P, Tillement JP, Testa B. 1998. Ligand specificity of the genetic variants of human α1-acid glycoprotein: generation of a three-dimensional quantitative structure-activity relationship model for drug binding to the A variant. Mol. Pharmacol. 54: 129-138.
31. Hochepied T, Berger FG, Baumann H, Libert C,. 2003. Alpha(1)-acid glycoprotein: an acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 14: 25-34.
32. Ishizaki J, Fukaishi A, Fukuwa C, Yamazaki S, Tabata M, Ishida T, Suga Y, Arai K, Yokogawa K, Miyamoto K,. 2010. Evaluation of selective competitive binding of basic drugs to alpha1-acid glycoprotein variants. Biol. Pharm. Bull. 33: 95-99.
33. Israili ZH, Dayton PG,. 2001. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab. Rev. 33: 161-235.
34. Kawasaki Y, Freire E,. 2011. Finding a better path to drug selectivity. Drug Discov. Today 16: 985-990.
35. Kremer JM, Wilting J, Janssen LH,. 1988. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol. Rev. 40: 1-47.
36. Kristensen CB,. 1983. Imipramine serum protein binding in healthy subjects. Clin. Pharmacol. Ther. 34: 689-694.
37. Kushner I, Mackiewicz A,. 1987. Acute phase proteins as disease markers. Dis. Markers 5: 1-11.
38. Ladbury JE, Klebe G, Freire E,. 2009. Adding calorimetric data to decision making in lead discovery: a hot tip. Nat. Rev. Drug Discov. 9: 23-27.
39. Lee BL, Sachdeva M, Chambers HF,. 1991. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. 35: 2505-2508.
40. Maruyama T, Otagiri M, Takadate A,. 1990. Characterization of drug binding sites on alpha 1-acid glycoprotein. Chem. Pharm. Bull. (Tokyo) 38: 1688-1691.
41. Maruyama T, Furuie MA, Hibino S, Otagiri M,. 1992. Comparative study of interaction mode of diazepines with human serum albumin and alpha 1-acid glycoprotein. J. Pharm. Sci. 81: 16-20.
42. Matsumoto K, Sukimoto K, Nishi K, Maruyama T, Suenaga A, Otagiri M,. Characterization of ligand binding sites on the alpha1-acid glycoprotein in humans, bovines and dogs. Drug Metab. Pharmacokinet. 2002; 17: 300-6.
43. Merrikin DJ, Briant J, Rolinson GN,. 1983. Effect of protein binding on antibiotic activity in vivo. J. Antimicrob. Chemother. 11: 233-238.
44. Miyoshi T, Sukimoto K, Otagiri M,. 1992. Investigation of the interaction mode of phenothiazine neuroleptics with alpha 1-acid glycoprotein. J. Pharm. Pharmacol. 44: 28-33.
45. Nakagawa T, Kishino S, Itoh S, Sugawara M, Miyazaki K,. 2003. Differential binding of disopyramide and warfarin enantiomers to human alpha(1)-acid glycoprotein variants. Br. J. Clin. Pharmacol. 56: 664-669.
46. Nakano M, Kakehi K, Tsai MH, Lee YC,. 2004. Detailed structural features of glycan chains derived from alpha1-acid glycoproteins of several different animals: the presence of hypersialylated, O-acetylated sialic acids but not disialyl residues. Glycobiology 14: 431-441.
47. Nishi K, Ueno M, Murakami Y, Fukunaga N, Akuta T, Kadowaki D, Watanabe H, Suenaga A, Maruyama T, Otagiri M,. 2009. A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein. J. Pharm. Sci. 98: 4316-4326.
48. Nishi K, Ono T, Nakamura T, Fukunaga N, Izumi M, Watanabe H, Suenaga A, Maruyama T, Yamagata Y, Curry S, Otagiri M,. 2011. Structural insights into differences in drug-binding selectivity between two forms of human α1-acid glycoprotein genetic variants, the A and F1 S forms. J. Biol. Chem. 286: 14427-14434.
49. Nix DE, Matthias KR, Ferguson EC,. 2004. Effect of ertapenem protein binding on killing of bacteria. Antimicrob. Agents Chemother. 48: 3419-3424.
50. Ohtaka H, Velazquez-Campoy A, Xie D, Freire E,. 2002. Overcoming drug resistance in HIV-1 chemotherapy: the binding thermodynamics of amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease. Protein Sci. 11: 1908-1916.
51. Ojala PJ, Hermansson M, Tolvanen M, Polvinen K, Hirvonen T, Impola U, Jauhiainen M, Somerharju P, Parkinnen J,. 2006. Identification of alpha-1 acid glycoprotein as a lysophospholipid binding protein: a complementary role to albumin in the scavenging of lysophosphatidylcholine. Biochemistry 45: 14021-14031.
52. Otagiri M, Yamamichi R, Imai T, Imamura Y, Takadate A,. 1988. Study on the binding of dicumarol to alpha 1-acid glycoprotein using circular dichroism spectroscopy. Chem. Pharm. Bull. (Tokyo) 36: 4958-4662.
53. Otagiri M, Yamamichi R, Maruyama T, Imai T, Suenaga A, Imamura Y, Kimachi K,. 1989. Drug binding to alpha 1-acid glycoprotein studied by circular dichroism. Pharm. Res. 6: 156-159.
54. Otagiri M, Miyoshi T, Yamamichi R, Maruyama T, Perrin JH,. 1991. Effects of tricyclic drug on induced circular dichroism spectra of dicumarol bound to alpha 1-acid glycoprotein. Biochem. Pharmacol. 42: 729-733.
55. Schmid K, Kaufmann H, Isemura S, Bauer F, Emura J, Motoyama T, Ishiguro M, Nanno S,. 1973. Structure of α1-acid glycoprotein. Complete amino acid sequence, multiple amino acid substitutions, and homology with the immunoglobulins. Biochemistry 12: 2711-2724.
56. Schmid K, Nimerg RB, Kimura A, Yamaguchi H, Binette JP,. 1977. The carbohydrate units of human plasma alpha1-acid glycoprotein. Biochim. Biophys. Acta 492: 291-302.
57. Schmidt S, Rock K, Sahre M, Burkhardt O, Brunner M, Lobmeyer MT, Derendorf H,. 2008. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob. Agents Chemother. 52: 3994-4000.
58. Schonfeld DL, Ravelli RB, Mueller U, Skerra A,. 2008. The 1.8-A crystal structure of alpha1-acid glycoprotein (orosomucoid) solved by UV RIP reveals the broad drug-binding activity of this human plasma lipocalin. J. Mol. Biol. 384: 393-405.
59. Skerra A., 2000. Lipocalins as a scaffold. Biochim. Biophys. Acta 1482: 337-350.
60. Taheri S, Cogswell LP 3rd, Gent A, Strichartz GR,. 2003. Hydrophobic and ionic factors in the binding of local anesthetics to the major variant of human alpha1-acid glycoprotein. J. Pharmacol. Exp. Ther. 304: 71-80.
61. Tellinghuisen J., 2008. Isothermal titration calorimetry at very low c. Anal. Biochem. 373: 395-397.
62. Treuheit MJ, Costello CE, Halsall HB,. 1992. Analysis of the five glycosylation sites of human alpha 1-acid glycoprotein. Biochem. J. 283 (Pt 1): 105-112.
63. Turnbull WB, Daranas AH,. 2003. On the value of c: can low affinity systems be studied by isothermal titration calorimetry? J. Am. Chem. Soc. 125: 14859-14866.
64. Urien S, Giroud Y, Tsai RS, Carrupt PA, Bree F, Testa B, Tillement JP,. 1995. Mechanism of ligand binding to alpha 1-acid glycoprotein (orosomucoid): correlated thermodynamic factors and molecular parameters of polarity. Biochem. J. 306 (Pt 2): 545-549.
65. Voulgari F, Cummins P, Gardecki TI, Beeching NJ, Stone PC, Stuart J,. 1982. Serum levels of acute phase and cardiac proteins after myocardial infarction, surgery, and infection. Br. Heart J. 48: 352-356.
66. Ward WH, Holdgate GA,. 2001. Isothermal titration calorimetry in drug discovery. Prog. Med. Chem. 38: 309-376.
67. Whelpton R., 1989. Ionization constants, octanol partition coefficients and cholinesterase inhibitor constants for chlorpromazine and its metabolites. J. Pharm. Pharmacol. 41: 856-858.
68. Wise R,. 1985. The relevance of pharmacokinetics to in-vitro models: protein binding-does it matter? J. Antimicrob. Chemother. 15 (Suppl A): 77-83.
69. Wise R., 1986. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin. Pharmacokinet. 11: 470-482.
70. Wiseman T., 1989. Rapid measurement of binding constants and heats of binding using a new titration calorimeter. Anal. Biochem. 179: 131-137.
71. Yamamoto M, Aki H,. 1988. Application of differential flow microcalorimetry for study of drug interactions in the blood system. J. Biochem. Biophys. Methods 16: 271-282.
72. Zini R, Copigneaux C, Tillement JP,. 1989. 1-Anilino-naphthalene 8-sulfonic acid (ANS) as a probe for the binding of antidepressant drugs to human alpha 1-acid glycoprotein (AAG). Prog. Clin. Biol. Res. 300: 417-421.
73. Zsila F, Mady G,. 2008. Biliverdin is the endogenous ligand of human serum alpha1-acid glycoprotein. Biochem. Biophys. Res. Commun. 372: 503-507.